Tolerogenic probiotics inhibited migratory potential of lupus patient-derived DCs by downregulating inflammatory chemokine receptors (CXCR3, CCR5, CCR4, CCR3), while enhancing regulatory DC traits through elevated indoleamine 2,3-dioxygenase (IDO) and IL-10 alongside reduced IL-12 (108). The gene discussed is CCR3; the disease is systemic lupus erythematosus.